Prescription Digital Therapeutics — CPB 0999 | AETNA Coverage Update

TL;DR: Aetna modified CPB 0999 covering prescription digital therapeutics, effective January 5, 2026. One product gets covered. Twenty-three don't. Here's what billing teams need to do.

Aetna's prescription digital therapeutics coverage policy under CPB 0999 draws a sharp line between one covered product and a long list of products the payer classifies as experimental. If your practice or organization bills for any of the digital therapeutic platforms listed below — across behavioral health, diabetes management, sleep, vision, or pelvic floor rehab — this policy directly affects your reimbursement and claim denial risk. The HCPCS codes referenced in CPB 0999 include A9291, A9292, A9293, E1905, G0552, G0553, G0554, S9002, and T1505.

Quick-Reference Table

Aetna Prescription Digital Therapeutics Coverage Criteria and Medical Necessity Requirements 2026

The Aetna prescription digital therapeutics coverage policy is narrow. One product meets medical necessity. Everything else is off the table.

What Aetna covers: FDA-cleared mobile apps for contraception based on fertility awareness. Natural Cycles is currently the only FDA-cleared fertility app that qualifies. Aetna covers one annual subscription to Natural Cycles per benefit period when prescribed by a treating provider. No additional supplies or services beyond that single annual subscription are covered.

This coverage exists because federal preventive care mandates require it — not because Aetna chose to cover it proactively. That's an important distinction for prior authorization purposes. If a patient's plan excludes preventive care or has specific exemptions, verify benefits before billing A9293.

Prior authorization requirements aren't explicitly detailed in CPB 0999 for Natural Cycles, but given the one-per-benefit-period limit, document the prescribing provider's order carefully. Any second subscription in the same benefit period will trigger a claim denial regardless of clinical justification.

For all other prescription digital therapeutics — the 23 platforms listed explicitly in the policy — Aetna's position is that insufficient peer-reviewed evidence supports their effectiveness. That's the stated basis for the experimental designation. The real billing implication is straightforward: claims for those platforms will not be reimbursed.

Aetna Prescription Digital Therapeutics Exclusions and Non-Covered Indications

This is where the policy does the most damage to PDT billing. Aetna classifies 23 prescription digital therapeutics as experimental, investigational, or unproven. These aren't gray-area products — they're explicitly named in CPB 0999.

The full list:

The breadth here is notable. This isn't a targeted exclusion of one product category. Aetna is drawing the line across the entire PDT space — behavioral health, sleep, diabetes, vision, neurology, rehab, and cardiology all have products on this list.

If your billing team has been submitting claims for any of these platforms, stop now. Those claims won't survive. Continuing to bill for these products after January 5, 2026 creates unnecessary denial volume and potential compliance exposure. See CPB 0999 for the specific HCPCS codes associated with these platforms.

Worth calling out specifically: reSET and reSET-O for substance use disorder and opioid use disorder both appear on this list. These were among the first FDA-authorized PDTs and generated significant industry momentum. Aetna's position signals that commercial payer adoption of PDT coverage isn't following the FDA clearance track — clinical evidence standards are the deciding factor.

Coverage Indications at a Glance

Aetna Prescription Digital Therapeutics Billing Guidelines and Action Items 2026

HCPCS Codes for Prescription Digital Therapeutics Under CPB 0999

Covered HCPCS Codes (When Medical Necessity Criteria Are Met)

HCPCS Codes Associated with Experimental PDTs

CPB 0999 lists the following codes in connection with prescription digital therapeutics classified as experimental, investigational, or unproven. Claims for the 23 named PDT products will be denied. The source policy does not specify which individual code maps to which named product — consult CPB 0999 directly to confirm code-level applicability for your claims.

No ICD-10-CM codes are specified in CPB 0999.